Advanced Pharmaceutical Solutions in Cardiology

Results of several major trials has been released on the past recent years to significantly reduce major cardiovascular events with an extraordinary impact in both pharmacological cardiologist’s therapeutic arsenal and public health economics.

FOURIER, CANTOS, COMPASS, PARADIGM-HF… are some of them and we will review how these landmark trials has changed the way cardiomyopathy patients are and will be treated today and in an early future.

KEYWORDS & TOPICS

Ischemic Cardiomyopathy, Diabetes and Cardiomyopathy, Adverse or Cardiovascular Events and LDL-C, Secondary CV Prevention, Inflammatory, thrombosis prevention.

CONFERENCES

Conference 1

Title: Advances and challenges in Cardiovascular treatment
Speaker: Ignacio Fernández Lozano
Institution: Hospital Puerta de Hierro, Madrid, Spain
E-mail: iflozano@secardiologia.es

Conference 2

Title: 2018: State of the art in Cardiology Pharmaceutical Solutions
Speaker: Luis Rodríquez Padial
Institution: Complejo Hospitalario de Toledo, Spain.
E-mail: lrpadial@secardiologia.es

Conference 3

Title: Reduced major cardiovascular events by using IPCSK9. Outcomes from the FOURNIER study
Speaker: Peter Sever
Institution: International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
E-mail: